Form 4: Lexicon Pharmaceuticals VP Alexander Reports Stock Transactions

Kristen Alexander, VP of Finance and Accounting at Lexicon Pharmaceuticals, reports the vesting and subsequent withholding of shares to cover tax obligations.

Summary

• Kristen Alexander, VP of Finance and Accounting at Lexicon Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2024, restricted stock units vested and were converted into common stock.
• A portion of the issued shares was withheld by the company to satisfy tax obligations.
• The reported transactions involved the vesting of 2,700, 10,616, and 15,927 restricted stock units.
• The price of the stock withheld for tax obligations was $2.62 per share.
• Following the reported transactions, Alexander directly owns 47,800 shares of Lexicon Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices involving stock-based compensation and tax withholding.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the issuance and subsequent withholding of shares related to executive compensation.

Key Dates